Roth Jeffrey E, Peer Cody J, Price Douglas K, Figg William D
Clinical Pharmacology Program; Office of the Clinical Director; National Cancer Institute; Bethesda, MD USA.
Cancer Biol Ther. 2014 Jan;15(1):16-8. doi: 10.4161/cbt.27149. Epub 2013 Nov 19.
The androgen receptor (AR) is central to the initiation and progression of prostate cancer, even after castration. Its transcriptional activity has previously been studied in cell lines. A group at the University of Cambridge recently outlined the AR transcriptional program in tissue samples, with an emphasis on castration-resistant tumors. AR binding sites, gene-expression changes (in xenografts), and potential transcription factor interactions were notably different from those observed in cultured cells. These discrepancies suggest a distinct signaling network for the AR in vivo and serve as a reminder that results from in vitro models should be checked against clinical realities.
雄激素受体(AR)对于前列腺癌的发生和发展至关重要,即使在去势后也是如此。此前已在细胞系中研究了其转录活性。剑桥大学的一个研究小组最近概述了组织样本中的AR转录程序,重点是去势抵抗性肿瘤。AR结合位点、基因表达变化(在异种移植中)以及潜在的转录因子相互作用与在培养细胞中观察到的显著不同。这些差异表明AR在体内有一个独特的信号网络,并提醒人们体外模型的结果应与临床实际情况进行对照检查。